In short
Currently, there is one ongoing clinical trial focused on treating brain inflammation caused by herpes simplex virus. This study is investigating whether adding a corticosteroid medication to standard antiviral treatment can improve long-term brain function and recovery in affected patients.
Clinical trial locations
Study on Dexamethasone for Patients with Herpes Simplex Virus Encephalitis
This clinical trial is examining whether dexamethasone, a corticosteroid medication, can improve recovery and brain function in patients with herpes simplex virus encephalitis, a serious brain infection. The study aims to determine if adding this anti-inflammatory medication to the standard antiviral treatment leads to better outcomes in memory and overall brain health six months after treatment begins.
Who can participate:
- Adults aged 18 years or older
- Patients with suspected encephalitis causing changes in consciousness, thinking, personality, or behavior lasting more than 24 hours
- Laboratory-confirmed herpes simplex virus infection through a PCR test on cerebrospinal fluid (the fluid surrounding the brain and spinal cord)
- Currently receiving aciclovir (an antiviral medication) through a vein at 10 mg per kilogram of body weight three times daily, or at an adjusted dose if kidney function is reduced
- Must be affiliated with social security
- Written informed consent provided by the patient or their legal representative
Who cannot participate:
- Children between 3 and 4 years of age
- Individuals considered part of a vulnerable population who may be at higher risk of harm or exploitation
What the trial involves:
Participants will receive either dexamethasone or a placebo (an inactive substance) in addition to their standard aciclovir treatment. The dexamethasone is given as an oral solution at a dose of 20mg/5ml. The medication works by reducing inflammation in the brain and modulating the immune system's response, which may help decrease swelling and pressure.
Throughout the study, patients will undergo regular assessments to monitor their recovery. Memory and cognitive abilities will be evaluated using standardized tests like the Wechsler Memory Scale at various time points: 30 days, 6 months, and 18 months after starting treatment. These evaluations measure memory, processing speed, and other thinking abilities.
The study also monitors other important health outcomes, including the occurrence of seizures, length of hospital stay, overall survival, and quality of life. Safety is tracked by checking for the presence of the virus in spinal fluid and monitoring other health indicators. Researchers will also assess anxiety, depression, and overall health status using standardized questionnaires at 6 and 18 months.
Investigational drug:
Dexamethasone is a corticosteroid medication that reduces inflammation and is being tested to see if it can improve long-term brain function outcomes in patients with this condition. It mimics hormones naturally produced by the adrenal glands and works by suppressing inflammation and modulating the immune response.
Summary
Currently, only one clinical trial is actively recruiting patients with herpes simplex virus encephalitis. This study is being conducted in France and represents an important effort to improve treatment outcomes for this serious brain infection. The focus of this research is on whether adding an anti-inflammatory medication to standard antiviral therapy can enhance recovery and preserve brain function, particularly memory and cognitive abilities. The trial's comprehensive approach includes long-term follow-up over 18 months, providing valuable information about both immediate and lasting effects of the treatment. Patients interested in participating should discuss this option with their healthcare providers to determine if they meet the eligibility criteria.
